Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables

Biometrical Journal

Volumn 54, Issue 5, 2012, Pages 716-729

  Sozu, Takashi ^a   Sugimoto, Tomoyuki ^b   Hamasaki, Toshimitsu ^c  

^a KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Biserial correlation; Intersection union test; Latent variable; Multiplicity; Multivariate normal

Indexed keywords

MEDICAL APPLICATIONS; SAMPLING;

BI-SERIAL CORRELATION; BINARY VARIABLES; CLINICAL TRIAL; CONTINUOUS VARIABLES; INTERSECTION UNION TESTS; LATENT VARIABLE; MULTIPLICITY; MULTIVARIATE NORMAL; SAMPLE SIZE DETERMINATION; SAMPLE SIZES;

NORMAL DISTRIBUTION;

EID: 84865547626     PISSN: 03233847     EISSN: 15214036     Source Type: Journal    
DOI: 10.1002/bimj.201100221     Document Type: Article

References (27)

1. Bartlett, M. S. (1947). The use of transformations. Biometrics 3, 39-52.
2. Breedveld, F. C., Weisman, M. H., Kavanaugh, A. F., Cohen, S. B., Pavelka, K., van Vollenhoven, R., Sharp, J., Perez, J. L. and Spencer-Green, G. T. (2006). The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis & Rheumatism 51, 26-37.
3. Committee for Medicinal Products for Human Use (2008). Guideline on Medicinal Products for the Treatment of Alzheimer's Disease and Other Dementias (CPMP/EWP/553/95 Rev.1). European Medicines Agency, London.
4. Dale, J. R. (1986). Global cross-ratio models for bivariate, discrete, ordered responses. Biometrics 42, 909-917.
5. Eaton, M. L. and Muirhead, R. J. (2007). On a multiple endpoints testing problem. Journal of Statistical Planning and Inference 137, 3416-3429.
6. Emrich, L. J. and Piedmonte, M. R. (1991). A method for generating high-dimensional multivariate binary variates. The American Statistician 45, 302-304.
7. Food and Drug Administration (2010). Daft Guidance for Industry. Irritable Bowel Syndrome: Clinical Evaluation of Products for Treatment. Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD.
8. Genz, A. (1992). Numerical computation of multivariate normal probabilities. Journal of Computational and Graphical Statistics 1, 141-150.
9. Hung, H. M. and Wang, S. J. (2009). Some controversial multiple testing problems in regulatory applications. Journal of Biopharmaceutical Statistics 19, 1-11.
10. Lev, J. (1949). The point biserial coefficient of correlation. The Annals of Mathematical Statistics 20, 125-126.
11. Molenberghs, G., Geys, H. and Buyse, M. (2001). Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes. Statistics in Medicine 20, 3023-3038.
12. Offen, W., Chuang-Stein, C., Dmitrienko, A., Littman, G., Maca, J., Meyerson, L., Muirhead, R., Stryszak, P., Boddy, A, Chen, K., Copley-Merriman, K., Dere, W., Givens, S., Hall, D., Henry, D., Jackson, J. D., Krishen, A., Liu, T., Ryder, S., Sankoh, A. J., Wang, J. and Yeh, C. H. (2007). Multiple co-primary endpoints: medical and statistical solutions. Drug Information Journal 41, 31-46.
13. Pearson, K. (1909). On a new method for determining the correlation between a measured character A, and a character B. Biometrika 7, 96-105.
14. Plackett, R. L. (1965). A class of bivariate distributions. Journal of the American Statistical Association 60, 516-522.
15. Prentice, R. L. (1998). Correlated binary regression with covariates specific to each binary observarion. Biometrics 44, 1033-1048.
16. Rudnick, M. R., Davidson, C., Laskey, W., Stafford, J. L. and Sherwin, P. F. (2008). VALOR Trial Investigators. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. American Heart Journal 156, 776-782.
17. Song, J. X. (2009). Sample size for simultaneous testing of rate differences in noninferiority trials with multiple endpoints. Computational Statistics & Data Analysis 53, 1201-1207.
18. Sozu, T., Kanou, T., Hamada, C. and Yoshimura, I. (2006). Power and sample size calculations in clinical trials with multiple primary variables. Japanese Journal of Biometrics 27, 83-96.
19. Sozu, T., Sugimoto, T. and Hamasaki, T. (2010). Sample size determination in clinical trials with multiple co-primary binary endpoints. Statistics in Medicine 29, 2169-2179.
20. Sozu, T., Sugimoto, T. and Hamasaki, T. (2011). Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints. Journal of Biopharmaceutical Statistics 21, 650-668.
21. Sugimoto, T., Sozu, T. and Hamasaki, T. (2012). A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints. Pharmaceutical Statistics 11, 118-128.
22. Tate, R. F. (1954). Correlation between a discrete and a continuous variable. Point-biserial correlation. The Annals of Mathematical Statistics 25, 603-607.
23. Tate, R. F. (1955a). The theory of correlation between two continuous variable when one is dichotomized. Biometrika 42, 205-216.
24. Tate, R. F. (1955b). Applications of correlation models for biserial data. Journal of the American Statistical Association 50, 1078-1095.
25. Walters, D. E. (1979). In defence of the arc sine approximation. The Statistician 28, 219-222.
26. Xiong, C., Yu, K., Gao, F., Yan, Y. and Zhang, Z. (2005). Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial. Clinical Trials 2, 387-393.
27. 2 test. Journal of the Royal Statistical Society, Suppl. 1, 217-235.